#2-95E. Targeting Amylin: Eloralintide Phase 2 Results (Lancet, 2025)

With the obesity pharmacotherapy landscape currently dominated by incretins, are we overlooking other potent biological pathways? This episode examines a pivotal Phase 2 trial published in The Lancet evaluating eloralintide, a novel selective amylin receptor agonist. The randomized, double-blind, placebo-controlled study assessed the efficacy of weekly subcutaneous injections over 48 weeks in adults with obesity or overweight, excluding those with type 2 diabetes. The results were robust, demonstrating that the 9 mg maintenance dose achieved a mean weight reduction of approximately 20%, significantly outperforming the placebo group. This finding highlights eloralintide’s potential as a powerful tool for weight management, potentially offering a distinct mechanism for patients intolerant to GLP-1 receptor agonists. However, critical appraisal is necessary, as the study is limited by relatively small sample sizes per treatment arm and a study population that was predominantly female and White, potentially limiting generalizability. For clinicians, staying abreast of this selective amylin pathway is essential as it represents a diversifying future for personalized obesity treatment options beyond current standards.

Citation: BILLINGS, L. K. et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025. DOI: 10.1016/S0140-6736(25)02155-5

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.